Supplemental Tables (S1-S3):

	Projected Peripartum/Intrauterine MTCT Risk (%) CD4>350 / CD4≤350[a]	Projected 6-Month Breastfeeding MTCT Risk (%) CD4>350 / CD4≤350[a]
Maternal ART		
Initiated ≤ 28 weeks GA	0.4[13]/ 0.6[12]	0.3[12] / 0.3[12]
Initiated 29-34 weeks GA	2.9[17]/ 3.7[17]	0.9[18]/ 1.1[17]
Initiated >34 weeks GA	2.9[17]/ 4.1[18]	0.9[18]/ 1.1[17]
Maternal ZDV monotherapy		
Initiated ≤ 34 weeks GA	3.4[17] / 6.3[17]	4.0[14] / 4.0[14]
Initiated >34 weeks GA	5.8[15]/ 11.6[15]	4.7[20] / 4.7[20]
Maternal sdNVP/ZDV in labor	6.6[19] / 18.4[19]	2.3[20] / 2.3[20]
No maternal antiretrovirals	21.8[16] / 33.2[16][b]	2.7[20] / 2.7[20]

Table S1: Duration of ARV model inputs.
Estimates of of risk of mother-to-child transmission by duration of maternal antiretrovirals and CD4 strata utilized in sensitivity analysis.
Note. MTCT, mother-to-child transmission; ART, combination antiretroviral therapy; GA, gestational age; ZDV, zidovudine; sdNPV, single-dose nevirapine

[a] CD4 strata were imputed for women without CD4 results following the distribution of CD4 counts in the study population.
[b] Calculated from Cox proportional hazards model.

	Projected MTCT		Difference (95% CI)	P-value
	Option A	Option B		
Spectrum model inputs				
Base	3.79%	4.69%	+ 0.90% (0.62-1.18)	<0.001
Low	2.76%	3.34%	+ 0.58% (0.40-0.76)	<0.001
High	4.77%	5.56%	+ 1.08% (0.72-1.44)	<0.001
Duration of ARV receipt inputs	4.87%	5.65%	+ 0.78% (0.45-1.10)	<0.001

Table S2: Sensitivity analyses of projected MTCT and impact of Option B.
Estimates of risk of mother-to-child transmission and effect estimates of impact of Option B implementation under the Spectrum model inputs and estimates utilizing duration of ARV receipt.
Note. MTCT, mother-to-child transmission; CI, confidence interval; ARV, antiretrovirals

	Effect estimate, Change in MTCT probability (95% CI)	P-value
WHO strategy		
Option A	—	—
Option B	+0.90 (0.62-1.18)	<0.001
Delivery hospital	—	<0.001
ANC location		
Urban (population >50,000)	—	—
Large village (population 20,000-50,000)	+ 0.16 (-0.15, 0.48)	0.31
Rural (population <20,000)	+ 0.23 (-0.02, 0.49)	0.068
ANC with onsite ART clinic	- 0.36 (-0.59, -0.13)	0.002
Receiving ART at conception	- 4.27 (-4.50, -4.05)	<0.001
Maternal age < 25 years	+ 0.21 (-0.07, 0.50)	0.065
Completed secondary education	- 0.31 (-0.59, -0.03)	0.028
Gestational at ANC registration (per each additional week)	+ 0.09 (0.07, 0.11)	<0.001
HIV diagnosis prior to pregnancy	- 0.45 (-0.73, -0.16)	0.002

Table S3: Estimates of effect from multivariate model of PMTCT strategy and other factors on probability of MTCT.
Note. MTCT, mother-to-child transmission; CI, confidence interval; WHO, World Health Organization; ANC, antenatal clinic; ART, combination antiretroviral therapy